SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works

Myocardial Fatty Acid Metabolism in Health and Disease

Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,180 · see citing works

Diabetic Cardiomyopathy

Jia, G., Hill, M. A., & Sowers, J. R. (2018) · Circulation Research · doi:10.1161/circresaha.117.311586 · Cited by 1,838 · see citing works

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975 · see citing works

Adipokines: molecular links between obesity and atheroslcerosis

Lau, D., Dhillon, B., Yan, H., Szmitko, P. E., & Verma, S. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01058.2004 · Cited by 930 · see citing works

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ^® trial

Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907 · see citing works

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · see citing works

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813 · see citing works

How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial

Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · see citing works

Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology

Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708 · see citing works

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2016) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 662 · see citing works

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation

Uthman, L., Baartscheer, A., Bleijlevens, B., Schumacher, C. A., Fiolet, J. W. T., Koeman, A., Jancev, M., Hollmann, M. W., Weber, N. C., Coronel, R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4509-7 · Cited by 612 · see citing works

Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes

Seferović, P. M., & Paulus, W. J. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv134 · Cited by 552 · see citing works

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507 · see citing works

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

Lee, T., Chang, N., & Lin, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 507 · see citing works

Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis

Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499 · see citing works

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032038 · Cited by 498 · see citing works

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program

Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488 · see citing works

Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease

Wanner, C., Lachin, J. M., Inzucchi, S. E., Fitchett, D., Mattheus, M., George, J., Woerle, H. J., Broedl, U. C., von Eynatten, M., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.028268 · Cited by 469 · see citing works

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

Kosiborod, M., Lam, C. S. P., Kohsaka, S., Kim, D. J., Karasik, A., Shaw, J. E., Tangri, N., Goh, S., Thuresson, M., Chen, H., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.009 · Cited by 462 · see citing works

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure

Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459 · see citing works

Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences

Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395 · see citing works

The effect of dapagliflozin treatment on epicardial adipose tissue volume

Sato, T., Aizawa, Y., Yuasa, S., Kishi, S., Fuse, K., Fujita, S., Ikeda, Y., Kitazawa, H., Takahashi, M., Sato, M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0658-8 · Cited by 381 · see citing works

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study

Solini, A., Giannini, L., Seghieri, M., Vitolo, E., Taddei, S., Ghiadoni, L., & Bruno, R. M. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0621-8 · Cited by 375 · see citing works

High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes

Boonman-de Winter, L. J. M., Rutten, F. H., Cramer, M. J. M., Landman, M. J., Liem, A. H., Rutten, G. E. H. M., & Hoes, A. W. (2012) · Diabetologia · doi:10.1007/s00125-012-2579-0 · Cited by 343 · see citing works

Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure

Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., & Zannad, F. M. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2275 · Cited by 335 · see citing works

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Sattar, N. A., McLaren, J. B., Kristensen, S. L., Preiss, D., & McMurray, J. J. V. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 310 · see citing works

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

McMurray, J. J. V., Gerstein, H. C., Holman, R. R., & Pfeffer, M. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70031-2 · Cited by 303 · see citing works

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Heise, T., Seewaldt-Becker, E., Macha, S., Hantel, S., Pinnetti, S., SEMAN, L. J., & Woerle, H. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12073 · Cited by 273 · see citing works

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Garvey, W. T., Gaal, L. V., Leiter, L. A., Vijapurkar, U., List, J. F., Cuddihy, R. M., Ren, J., & Davies, M. J. (2018) · Metabolism · doi:10.1016/j.metabol.2018.02.002 · Cited by 261 · see citing works

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx511 · Cited by 242 · see citing works

Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study

Gormsen, L. C., Svart, M. V., Thomsen, H. H., Søndergaard, E., Vendelbo, M. H., Christensen, N. L., Tolbod, L. P., Harms, H. J., Nielsen, R. R., Wiggers, H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005066 · Cited by 235 · see citing works

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics

Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology · doi:10.1159/000484633 · Cited by 234 · see citing works

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

Verma, S., Garg, A., Yan, A. T.-K., Gupta, A. K., Al-Omran, M. A., Sabongui, A., Teoh, H., Mazer, C. D., & Connelly, K. A. (2016) · Diabetes Care · doi:10.2337/dc16-1312 · Cited by 233 · see citing works

Epicardial adipose tissue as a metabolic transducer: Role in heart failure and coronary artery disease

Patel, V. B., Shah, S., Verma, S., & Oudit, G. Y. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9644-1 · Cited by 218 · see citing works

Cardiac remodeling and failure

Fedak, P. W. M., Verma, S., Weisel, R. D., & Li, R. (2005) · Cardiovascular Pathology · doi:10.1016/j.carpath.2004.12.002 · Cited by 215 · see citing works

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

Januzzi, J. L., Butler, J., Jarolı́m, P., Sattar, N. A., Vijapurkar, U., Desai, M. G., & Davies, M. J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.016 · Cited by 208 · see citing works

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

Karg, M. V., Bosch, A., Kannenkeril, D., Striepe, K., Ott, C., Schneider, M. P., Boemke-Zelch, F., Linz, P. R., Nagel, A. M., Titze, J. M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0654-z · Cited by 188 · see citing works

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Bansilal, S., Bhatt, D. L., Leiter, L. A., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.012 · Cited by 180 · see citing works

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure

Byrne, N. J., Parajuli, N., Levasseur, J. L., Boisvenue, J., Beker, D. L., Masson, G., Fedak, P. W. M., Verma, S., & Dyck, J. R. B. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.003 · Cited by 172 · see citing works

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus

Striepe, K., Jumar, A., Ott, C., Karg, M. V., Schneider, M. P., Kannenkeril, D., & Schmieder, R. E. (2017) · Circulation · doi:10.1161/circulationaha.117.029529 · Cited by 169 · see citing works

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME

Verma, S., Mazer, C. D., Al-Omran, M., Inzucchi, S. E., Fitchett, D., Hehnke, U., George, J. T., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.032031 · Cited by 166 · see citing works

Moderated ePoster Session 2

Butler, J., HAMO, C. E., Filippatos, G. S., Pocock, S., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.933 · Cited by 165 · see citing works

Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial

Inzucchi, S. E., Iliev, H., Pfarr, E., & Zinman, B. (2018) · Diabetes Care · doi:10.2337/dc17-1551 · Cited by 162 · see citing works

The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition

Verma, S., McMurray, J. J. V., & Cherney, D. Z. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1891 · Cited by 158 · see citing works

Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

Kappel, B. A., Lehrke, M., Schütt, K. S., Artati, A., Adamski, J., Lebherz, C., & Marx, N. (2017) · Circulation · doi:10.1161/circulationaha.117.029166 · Cited by 155 · see citing works

The diabetic heart utilizes ketone bodies as an energy source

Mizuno, Y., Harada, E., Nakagawa, H., Morikawa, Y., Shono, M., Kugimiya, F., Yoshimura, M., & Yasue, H. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.005 · Cited by 150 · see citing works

Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects

Wilcox, C. S., Shen, W., Boulton, D. W., Leslie, B. R., & Griffen, S. C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007046 · Cited by 139 · see citing works

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

SEMAN, L. J., Macha, S., Nehmiz, G., Simons, G., Ren, B., Pinnetti, S., Woerle, H. J., & Dugi, K. A. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.16 · Cited by 136 · see citing works

Empagliflozin’s Fuel Hypothesis: Not so Soon

Lopaschuk, G. D., & Verma, S. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.018 · Cited by 132 · see citing works

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Verma, S., Mazer, C. D., FITCHETT, D. H., Inzucchi, S. E., Pfarr, E., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4644-9 · Cited by 125 · see citing works

Cardiac remodeling and failure

Fedak, P. W. M., Verma, S., Weisel, R. D., & Li, R.-K. (2005) · Cardiovascular Pathology · doi:10.1016/j.carpath.2005.01.005 · Cited by 120 · see citing works

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

Verma, S., Bhatt, D. L., Bain, S. C., Buse, J. B., Mann, J. F. E., Marso, S. P., Nauck, M. A., Poulter, N. R., Pratley, R. E., Zinman, B., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.033898 · Cited by 105 · see citing works

Do sodium‐glucose co‐transporter‐2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis

Packer, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13229 · Cited by 101 · see citing works

The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels

Li, H., Shin, S. E., Seo, M. S., An, J. R., Choi, I., Jung, W., Firth, A. L., Lee, D.-S., Yim, M., Choi, G., et al. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.01.032 · Cited by 101 · see citing works

Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure

Swoboda, P., McDiarmid, A. K., Erhayiem, B., Ripley, D. P., Dobson, L. E., Garg, P., Musa, T. A., Witte, K. K., Kearney, M. T., Barth, J. H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005539 · Cited by 89 · see citing works

Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?

Shi, X., Verma, S., Yun, J., Brand‐Arzamendi, K., Singh, K. K., Liu, X., Garg, A., Quan, A., & Wen, X. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3018-9 · Cited by 75 · see citing works

Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes

Jobori, H. A., Daniele, G., Cersósimo, E., Triplitt, C. L., Mehta, R. J., Norton, L., DeFronzo, R. A., & Abdul-Ghani, M. A. (2017) · Diabetes · doi:10.2337/db17-0100 · Cited by 67 · see citing works

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design

Singh, J. S., Fathi, A., Vickneson, K., Mordi, I. R., Mohan, M., Houston, J. G., Pearson, E. R., Struthers, A. D., & Lang, C. C. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0419-0 · Cited by 61 · see citing works

Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes.

Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56 · see citing works

EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY

Santos‐Gallego, C. G., Ibáñez, J. A. R., Antonio, R. S., Ishikawa, K., Watanabe, S., Botija, M. B. P., Salvo, A. S., Hajjar, R. J., Fuster, V., & Badimón, J. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(18)31215-4 · Cited by 32 · see citing works

DIRECT EFFECTS OF EMPAGLIFLOZIN ON EXTRACELLULAR MATRIX REMODELING IN HUMAN CARDIAC FIBROBLASTS: NOVEL TRANSLATIONAL CLUES TO EMPA-REG OUTCOME

Kang, S., Verma, S., Teng, G., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.07.330 · Cited by 29 · see citing works

Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia

Sherman, S. E., Bell, G. I., Teoh, H., Al-Omran, M. A., Connelly, K. A., Bhatt, D. L., Hess, D. A., & Verma, S. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.010 · Cited by 23 · see citing works

Heart Failure

Jorsal, A., Wiggers, H., & McMurray, J. J. V. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.007 · Cited by 19 · see citing works

Prevention of Heart Failure With SGLT-2 Inhibition

Farkouh, M. E., & Verma, S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.078 · Cited by 13 · see citing works

Response by Figtree et al to Letter Regarding Article, “Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)”

Figtree, G. A., Rådholm, K., & Neal, B. C. (2019) · Circulation · doi:10.1161/circulationaha.118.038477 · Cited by 5 · see citing works

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140 · see citing works

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862 · see citing works

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922 · see citing works

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · see citing works

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036 · see citing works

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA · doi:10.1001/jama.2020.1906 · Cited by 531 · see citing works

Hypoxia signaling in human health and diseases: implications and prospects for therapeutics

Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499 · see citing works

Cardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention

Wong, N. D., & Sattar, N. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00877-z · Cited by 495 · see citing works

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466 · see citing works

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455 · see citing works

A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)

McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1432 · Cited by 433 · see citing works

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042929 · Cited by 424 · see citing works

Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease

Mazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044235 · Cited by 371 · see citing works

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects

Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300 · see citing works

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

Lingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30311-0 · Cited by 298 · see citing works

The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics

McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1548 · Cited by 222 · see citing works

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis From the EMPRISE Study

Patorno, E., Pawar, A., Franklin, J. M., Najafzadeh, M., Déruaz-Luyet, A., Brodovicz, K. G., Sambevski, S., Bessette, L. G., Santiago Ortiz, A. J., Kulldorff, M., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039177 · Cited by 215 · see citing works

Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors

Wilcox, C. S. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.11684 · Cited by 167 · see citing works

The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms

Salvatore, T., Pafundi, P. C., Galiero, R., Albanese, G., Di Martino, A., Caturano, A., Vetrano, E., Rinaldi, L., & Sasso, F. C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.695792 · Cited by 165 · see citing works

Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study

Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., Renoux, C., Suissa, S., & Azoulay, L. (2024) · BMJ · doi:10.1136/bmj-2023-078242 · Cited by 151 · see citing works

Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system

Puglisi, S., Rossini, A., Poli, R., Dughera, F., Pia, A., Terzolo, M., & Reimondo, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.738848 · Cited by 143 · see citing works

SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation

Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes · doi:10.2337/dbi20-0040 · Cited by 123 · see citing works

Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT Trial

Scholtes, R. A., Muskiet, M. H. A., van Baar, M. J. B., Hesp, A. C., Greasley, P. J., Karlsson, C., Hammarstedt, A., Arya, N., van Raalte, D. H., & Heerspink, H. J. L. (2021) · Diabetes Care · doi:10.2337/dc20-2604 · Cited by 125 · see citing works

Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure

Scheen, A. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1165-1 · Cited by 122 · see citing works

&lt;p&gt;Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide&lt;/p&gt;

Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103 · see citing works

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies

Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86 · see citing works

Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes

Garg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82 · see citing works

<scp>SGLT2</scp> inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the <scp>HIF</scp> ‐2α signaling pathway in arrhythmogenic cardiomyopathy

Yang, Z., Li, T., Xian, J., Chen, J., Huang, Y., Zhang, Q., Lin, X., Lu, H., & Lin, Y. (2022) · The FASEB Journal · doi:10.1096/fj.202200243r · Cited by 79 · see citing works

Glucocorticoid-Induced Hyperglycemia: A Neglected Problem

Cho, J.-H., & Suh, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1951 · Cited by 63 · see citing works

GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection

Bertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49 · see citing works

Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48 · see citing works

An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis

Balogh, D. B., Wagner, L. J., & Fekete, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097789 · Cited by 38 · see citing works

Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor

Marinkovic-Radosevic, J., Cigrovski Berkovic, M., Kruezi, E., Bilic-Curcic, I., & Mrzljak, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i7.932 · Cited by 35 · see citing works

Alternative strategies in cardiac preclinical research and new clinical trial formats

Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36 · see citing works

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

Weir, M. R., Slee, A., Sun, T., Balis, D., Oh, R., de Zeeuw, D., & Perkovic, V. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa133 · Cited by 31 · see citing works

Role of Glucose-Lowering Medications in Erectile Dysfunction

Cignarelli, A., Genchi, V. A., D’Oria, R., Giordano, F., Caruso, I., Perrini, S., Natalicchio, A., Laviola, L., & Giorgino, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112501 · Cited by 30 · see citing works

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis

Cignarelli, A., Genchi, V. A., Le Grazie, G., Caruso, I., Marrano, N., Biondi, G., D’Oria, R., Sorice, G. P., Natalicchio, A., Perrini, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.846903 · Cited by 24 · see citing works

Role of atrial peptide in the natriuresis and diuresis that follows relief of obstruction in rat

Purkerson, M. L., Blaine, E. H., Stokes, T. J., et al. (1989) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1989.256.4.f583 · Cited by 33 · see citing works

Volume Expansion Enhances the Recovery of Renal Function and Prolongs the Diuresis and Natriuresis After Release of Bilateral Ureteral Obstruction: A Possible Role for Atrial Natriuretic Peptide

Gulmi, F. A., Matthews, G. J., Marion, D. N., et al. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67585-2 · Cited by 26 · see citing works

Bradykinin (BK) Enhances Diuresis and Natriuresis in Saline Volume-Expanded Dogs

Honda, K., Nunokawa, A., & NAGASAKA, M. (1989) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-9543-4_42

Urine Reinfusion Diuresis and Natriuresis in Rats: Role of Water, Electrolytes and Urea

Norman, R. A., Coleman, T. G., & Kastner, P. R. (1979) · Clinical Science · doi:10.1042/cs0570187

Paradoxical relationship between atriopeptin plasma levels and diuresis-natriuresis induced by acute volume expansion.

Sakata, M., Greenwald, J. E., & Needleman, P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.9.3155 · Cited by 23 · see citing works